Administration of lower doses of radium-224 to ankylosing spondylitis patients results in no evidence of significant overall detriment
Autor: | David G. Hoel, Nicholas D. Priest, Lawrence T. Dauer |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Male
Neoplasms Radiation-Induced Time Factors Ankylosing Spondylitis Cancer Treatment 030218 nuclear medicine & medical imaging Hematologic Cancers and Related Disorders 0302 clinical medicine Cause of Death Epidemiology Medicine and Health Sciences Cause of death Aged 80 and over education.field_of_study Osteosarcoma Multidisciplinary Leukemia Incidence (epidemiology) Thorium Sarcomas Radiotherapy Dosage Hematology Middle Aged Chemistry Oncology 030220 oncology & carcinogenesis Injections Intravenous Physical Sciences Medicine Radium Research Article Chemical Elements Adult medicine.medical_specialty Death Rates Inflammatory Diseases Science Population Immunology Autoimmune Diseases 03 medical and health sciences Safety-Based Drug Withdrawals Chlorides Population Metrics Internal medicine Leukemias medicine Humans Spondylitis Ankylosing education Spondylitis Aged Ankylosing spondylitis Population Biology Proportional hazards model business.industry Case-control study Chemical Compounds Cancers and Neoplasms Biology and Life Sciences Dose-Response Relationship Radiation medicine.disease Case-Control Studies Clinical Immunology Clinical Medicine business Follow-Up Studies |
Zdroj: | PLoS ONE, Vol 15, Iss 4, p e0232597 (2020) PLoS ONE |
ISSN: | 1932-6203 |
Popis: | The use of low doses of radium-224 (224Ra) chloride for the treatment of ankylosing spondylitis was stopped following the discovery that patients treated with it had a higher than control incidence of leukaemia and other cancers. This was so even though the treatment resulted in decreased pain and increased mobility-both of which are associated with decreased mortality. It was decided to re-analyze the epidemiological data looking at all causes of death. The risk of leukaemia, solid cancer, death from non-cancer causes and from all causes in a study populations of men that received either the typical dose of 5.6 to 11.1 MBq of 224Ra, any dose of 224Ra or no radium were compared using the Cox proportional hazard model. For patients that received the typical dose of 224Ra agreed with the excess cancer was similar to that reported in previous studies. In contrast, these patients were less likely to die from non-cancer diseases and from all causes of death than the control patients. No excess mortality was also found in the population of all males that received the radionuclide. It is concluded that 224Ra treatment administered at low doses to patients with ankylosing spondylitis did not impact mortality from all causes. The study demonstrates the need to consider all causes of death and longevity when assessing health impacts following irradiation. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |